Howard Maibach, MD

Cutaneous leukocytoclastic vasculitis due to erlotinib: just an adverse event or also a putative marker of drug efficacy? (23534992)

Brandi G, Venturi M, Dika E, Maibach H, Patrizi A, Biasco G PMID: 23534992

Do partition coefficients (liphophilicity/hydrophilicity) predict effects of occlusion on percutaneous penetration in vitro: a retrospective review. (23535019)

Hafeez F, Maibach H PMID: 23535019

Climate and skin function: an overview. (23521370)

Singh B, Maibach H PMID: 23521370

Application site adverse events associated with the buprenorphine transdermal system: a pooled analysis. (23506252)

Wen W, Lynch SY, Munera C, Swanton R, Ripa SR, Maibach H PMID: 23506252

Skin benefits with a novel emollient-treated menstrual pad. (23259459)

Farage MA, Miller KW, Azuka CE, Wang B, Lankhof S, Henn D, Messerschmidt A, Goldhammer A, Wilhelm KP, Maibach HI PMID: 23259459

North American Contact Dermatitis Group patch test results: 2009 to 2010. (23474444)

Warshaw EM, Belsito DV, Taylor JS, Sasseville D, DeKoven JG, Zirwas MJ, Fransway AF, Mathias CG, Zug KA, DeLeo VA, Fowler JF, Marks JG, Pratt MD, Storrs FJ, Maibach HI PMID: 23474444

Characteristics of the Aging Skin. (24527317)

Farage MA, Miller KW, Elsner P, Maibach HI PMID: 24527317

Occlusion effect on in vivo percutaneous penetration of chemicals in man and monkey: partition coefficient effects. (23327987)

Hafeez F, Maibach H PMID: 23327987

Bioequivalence in keratolytic activity of formulations vs its vehicle and comparator formulation: randomized, double-blind clinical trial. (23540073)

Zhai H, Zheng Y, Matravers P, Hicks DA, Wiener S, Maibach HI PMID: 23540073

North American Contact Dermatitis Group patch test results for 2007-2008. (23340394)

Fransway AF, Zug KA, Belsito DV, Deleo VA, Fowler JF, Maibach HI, Marks JG, Mathias CG, Pratt MD, Rietschel RL, Sasseville D, Storrs FJ, Taylor JS, Warshaw EM, Dekoven J, Zirwas M PMID: 23340394